NCT00261313View on ClinicalTrials.gov

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

December 31, 2007

Conditions
Breast Cancer
Interventions
DRUG

Neulasta

6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy

DRUG

Aranesp

If Hb drops below 110, 300mcg Aranesp will be administered.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY